RMRobert Malcolm

Robert Malcolm

*This is an algorithmically generated author record based on publicly available information.

Robert Malcolm has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improving Musculoskeletal Care Quality With a Web-Based Clinical Decision Support System in UK Primary Care: Mixed Methods Cluster-Randomized Controlled Trial

    by Jonathan Hill, Hollie Birkinshaw, Muhammed Usman, Tammy Millward, James Bailey, Simon Wathall, Rebecca Naylor, Robert Malcolm, Melissa Pegg, Hayden Holmes, et al.

    Background: Musculoskeletal (MSK) conditions account for one in seven general practice consultations in the United Kingdom. Despite national guidelines, suboptimal care remains common. Digital clinical decision support systems (CDSSs) offer a promising route to improve care quality but have not been robustly evaluated in MSK primary care. Objective: This study aimed to evaluate the efficacy, clinical effectiveness and cost-effectiveness, carbon reduction, safety, and implementation of a CDSS (CrossCover) for MSK consultations in UK general practice. Methods: We conducted a mixed methods, cluster-randomized controlled trial in 19 general practices between February and July 2024. Practices were randomized 1:1, stratified by list size. Intervention practices received training and access to the web-based CDSS for 3 months. We analyzed anonymized electronic health records to identify all adult MSK consultations. The primary outcome was the proportion of patient records containing one or more of 12 predefined non–evidence-based management options, assessed by blinded clinical review of 120 patient records (60 per arm). Reviewers assessed the complete 3-month record in both arms; in the intervention arm, suboptimal management was counted only where it occurred at a consultation in which the CDSS was used. Secondary outcomes included intention-to-treat treatment comparisons of self-management advice, prescriptions, referrals, and imaging. Clinician engagement, safety, environmental and economic modeling, and clinician experiences from semistructured interviews were evaluated. Outcome assessors were blinded; clinicians were not. Results: Among 10,182 eligible patients with MSK conditions (4268 intervention; 5914 control), the CDSS was used in 365 (8.6%) patient cases. Intention-to-treat analysis identified that the intervention increased self-management alone. Per-protocol analysis demonstrated that when used, suboptimal care arose in 3% (2/60) of CDSS-guided consultations vs 25% (15/60) of control consultations (adjusted odds ratio 12.30, 95% CI 2.52‐59.9; P =.002). It also increased self-management advice and community referrals, and it reduced prescribing and fit-note use. Safety concerns were logged in 6.6% (24/365) of uses with no high-risk issues identified. Environmental modeling estimated an 18% reduction in carbon emissions and 10% annual cost savings if the intervention were scaled. Interviews (n=18) highlighted positive perceptions of the CDSS’s content and safety netting but noted challenges in integration. Conclusions: When used, the CrossCover CDSS significantly reduced suboptimal primary care MSK management. However, while safety and clinician feedback were favorable, overall engagement was limited, underscoring the need for improved digital integration, workflow alignment, and implementation support.


  • Open Access

    Economic and health impact of integrating smoking cessation services into NHS cancer care pathways in England: a modelling study

    by Maisie Green, Sam Harper, Ellen Telfer-Thomas, Sanjay Agrawal, Matthew E.J. Callister, Jenna L. Lane, Graham Warren, Rachael L. Murray, Matthew Evison, Mahdi Sheikh, et al.

  • Open Access

    Cost-effectiveness of prehabilitation across the lung cancer treatment pathway: a UK health economic modelling study

    by Matthew Evison, Catherine Sandsund, Luc Curtis-Gretton, Maisie Green, Adam Januszewski, Robert Malcolm, Zoe Merchant, Katie Murray, Andriana Petrova, Iain Phillips, et al.

    Highlights• First economic evaluation of prehabilitation across the whole lung cancer pathway• Cost-effective in early-stage (£3,019/QALY) and late-stage (£6,040/QALY) disease• Remained cost-saving when all survival benefit was removed from the model• Greatest benefit accrued to the most deprived quintile, suggesting reduced inequity• Supports commissioning prehabilitation for all lung cancer patients

  • Open Access

    Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening

    by H. Fewster, P. Nuttall, M. Evison, H. Holmes, R. Malcolm

    Lung cancer is a leading cause of cancer death, and smoking-related disease is a major cause of health inequality in England, driven by increased prevalence of smoking in deprived areas. Integrating smoking cessation support into the English Lung Cancer Screening (LCS) programme may optimize services and has been found cost-effective. However, limited evidence is available on its health equity impact. The objective was to conduct an aggregate distributional cost-effectiveness analysis (DCEA) of providing smoking cessation as part of LCS compared with usual care (referral to stop smoking services) to estimate its impact on health inequalities and health-related social welfare in England. The DCEA used an aggregate approach, stratifying people who smoke, aged 55-74 who were attending LCS by Index of Multiple Deprivation (IMD) quintiles. Discounted incremental costs and quality-adjusted life years (QALYs) were derived from a Markov model, adapted from previous NICE guidelines. The base case analysis applied a Health Opportunity Cost (HOC) of £15,000 per QALY and an Atkinson inequality aversion parameter (IAP) of 6.5, assuming a equal distribution across groups for intervention uptake. Under all base case assumptions, smoking cessation provided as part of targeted LCS had a positive net health benefit and health equity impact. The intervention dominated usual care, resulting in a total net health benefit of 142,035 QALYs. The distribution of benefit strongly favored the most deprived quintile (IMD1: 34,863 QALYs vs. IMD5: 23,612 QALYs), driven by smoking prevalence. Reforming smoking cessation services as part of LCS would likely improve both population health and health equity. Uptake of smoking cessation is a key determinant of the impact on health inequalities, underscoring the importance of targeted implementation strategies for optimizing population health, while reducing health inequalities.

  • Open Access

    PD229 “It’s All About Layers”: Painting The Picture Of Health Inequalities For Health Technology Assessment

    by Robert Malcolm, Sam Woods, Hayden Holmes

    Introduction: Health inequalities can be described as avoidable, systematic, and unjust differences in health between different groups within society. This research described and evaluated potential methods to measure the effects of health inequalities that could be used in health technology assessment (HTA) in the UK. The research included recommendations for current and future policy objectives relating to incorporating health inequalities.Methods: A targeted literature review was conducted to identify methodological approaches used to incorporate health inequalities in HTA. Stakeholder interviews and a workshop were conducted with a range of stakeholders in the UK. This engagement aimed to discuss any gaps in the literature and to assess whether attitudes, methods, and policies were evolving at the same rate as the literature. Other aims of the engagement included obtaining stakeholder views on health inequalities and a better understanding of the perspectives of decision-makers.Results: Five potential methods were identified to account for health inequalities, with equity-based weighting and distributional cost-effectiveness analysis considered to be the most feasible quantification methods. Stakeholders reiterated that a deliberative process should remain the center of HTA. Stakeholders also raised issues such as the burden on committees, trade-offs between complexity and accessibility, and the importance of measuring the size and direction of inequality impacts. Recommendations were then produced based on these findings to better account for inequalities in HTA, highlighting the importance of combining a range of approaches.Conclusions: Both companies and HTA agencies should be more proactive in accounting for health inequalities. Companies should be encouraged to provide quantitative analysis on health inequalities, while decision-makers should be trained in new methods. Despite the recent rise in quantitative methods, qualitative methods remain extremely important for a layered approach to considering health inequalities.

  • Open Access

    OP16 “Progress Is Impossible Without Change”: A Case Study To Feasibly Incorporate Environmental Sustainability In Health Technology Assessment

    by Robert Malcolm, Rebecca Naylor, Melissa Pegg

    Introduction: Environmental sustainability and its incorporation in health technology assessment (HTA) is becoming increasingly researched globally. However, this has yet to lead to a significant impact on HTA processes. This research presents a novel case study, demonstrating how available methods can deepen the understanding of evidence-based approaches to healthcare decision-making and support HTA sustainability policy development.Methods: A decision-analytic model was developed for a digital health technology used to support primary care in the diagnosis and triage of musculoskeletal conditions. The model mapped the potential impact on the care pathway, capturing differences in resource use, including appointments, medications, diagnostic tests, surgical procedures, and other nonpharmacological treatments. The model was populated from a UK perspective and captured both health economic impact and carbon dioxide equivalents (CO2e) impact. Additional potential environmental impacts were then considered qualitatively as part of the evaluation.Results: The health economic modeling approach captures all stages of the patient care pathway and resource use demonstrating its practicality for simultaneously mapping out the carbon impacts. This methodological approach is reproducible, transparent, and provides a standardized tool for use in future carbon-cost-comparison modeling. This would present decision-makers with more complete information. There are some limitations to this approach, such as ambiguity regarding some carbon data estimates used, but it still provides a more useful summary than no estimated quantification.Conclusions: Adapting HTA will support wider efforts in health systems to reduce environmental impacts. This model can be practically applied to account for both cost and carbon data, facilitating a holistic and environmentally sustainable approach to decision-making. As part of encouraging additional research into the environment, HTA agencies will need to provide “incentives” for companies to undertake this additional research.

  • Open Access

    PP07 One Bad Apple Can Spoil The Barrel: Are We Effectively Evaluating Software As A Medical Device?

    by Luc Curtis-Gretton, Robert Malcolm

    Introduction: There are many differences between medical devices, pharmaceuticals, and Software as a Medical Device (SaMD). This should impact the way SaMDs are evaluated in health technology assessment (HTA). SaMD technologies often target multiple indications, are regularly updated, and often result in non-quantifiable benefits. The objective of this research was to identify problems and potential solutions when evaluating SaMDs in England.Methods: This research took the perspective of the HTA process in England. We conducted a pragmatic review of publicly available grey literature, such as National Institute for Health and Care Excellence (NICE) guidelines and processes, government schemes, funding mechanisms, and other published reports and opinion pieces, to summarize how SaMDs are currently being evaluated. This included an overview of the current systems and funding structures (inclusive of recent developments), where potential issues may lie, and what is currently being done to address these issues. We concluded by making recommendations to improve the evaluation of these technologies.Results: Difficulty quantifying outcomes of SaMD technologies, alongside the preference of decision-makers to evaluate technologies for single indications, causes a bottleneck of unevaluated technologies to build. HTA bodies then group many non-identical technologies into single appraisals, resulting in a range of SaMD technologies with varying quality being implemented through managed access agreements. Some schemes and funding mechanisms led by public bodies in England aim to improve efficiency and encourage technological development. However, the HTA process in England remains characterized by long evaluation processes and high clinical evidence requirements, which many SaMD providers find difficult to navigate.Conclusions: Although progress has been made, there is clear incentive to improve the way in which SaMD technologies are assessed in HTA. We recommend that a more rapid mixed-method approach be implemented. This should draw on quantitative economic analysis supplemented with qualitative clinical, patient, and expert opinion. SaMDs should be evaluated either individually or within smaller groups than current evaluation systems.

  • Open Access

    An exploratory cost-effectiveness analysis of a novel tissue valve compared with mechanical valves for surgical aortic valve replacement in subgroups of people aged 55–64 and 65+ with aortic stenosis in the UK

    by Robert Malcolm, Ciara Buckley, Judith Shore, Angela Stainthorpe, Belen Marti, Andrea White, Jens Deckert, Matteo Vernia, João L. Carapinha, Ana López-Marco, et al.

    Exploratory analysis to conceptualize and evaluate the potential cost-effectiveness and economic drivers of using a novel tissue valve compared with mechanical heart valves for surgical aortic valve replacement (SAVR) in people aged 55-64 and 65+ with aortic stenosis (AS) from a National Health Service (NHS) UK perspective. A decision-analytic model was developed using a partitioned survival model. Parameter inputs were obtained from published literature. Deterministic and probabilistic sensitivity analyses (DSA and PSA) were conducted to explore the uncertainty around the parameters. The novel tissue valve was potentially associated with higher quality-adjusted life years (QALYs) of 0.01 per person. Potential cost savings were greatest for those aged 55-64 (£408) versus those aged 65+(£53). DSA indicated the results to be most dependent on relative differences in general mortality, procedure costs, and reoperation rates. PSA estimated around 75% of the iterations to be cost-effective at £20,000 per QALY for those aged 55-64, and 57% for those aged 65+. The exploratory analysis suggests that the novel tissue valve could be a cost-effective intervention for people over the age of 55 with AS who are suitable for SAVR in the UK.


  • Open Access

    Economic evaluation of a vision-based patient monitoring and management system in an acute adult and an older adult mental health hospital in England

    by Robert Malcolm, Judith Shore, Angela Stainthorpe, Faith Ndebele, Kay Wright

    Patients on acute adult and older adult inpatient mental health wards are at an increased risk of accidental injuries and deliberate harm to self and others. A vision-based patient monitoring and m...


  • Open Access

    Economic evaluation of a vision-based patient monitoring and management system in addition to standard care for adults admitted to psychiatric intensive care units in England

    by Robert Malcolm, Judith Shore, Angela Stainthorpe, Faith Ndebele, Kay Wright

    Treating patients in psychiatric intensive care units (PICUs) is costly for the English National Health Service (NHS), requiring significant staff time. Oxevision, a non-contact system, providing v...